We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Kathleen M. Gustafson is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2009 — 2010 |
Gustafson, Kathleen M |
R21Activity Code Description: To encourage the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) |
The Effects of Docosahexaenoic Acid (Dha) On Fetal Cardiac Outcomes @ University of Kansas Medical Center
DESCRIPTION (provided by applicant): Docosahexaenoic acid (DHA, 22:6n-3) is a long-chain polyunsaturated fatty acid member of the n-3 fatty acid family. DHA is important in early development, both in terms of the reproductive physiology of gestation and in postnatal behavioral and cognitive function. In adults, DHA has been shown to lower triglycerides and is important to cardiovascular health and autonomic control, lowering heart rate (HR) and blood pressure and increasing heart rate variability (HRV). However, very little is known about how n-3 fatty acids impact cardiac autonomic control in infants, children or the fetus. In the course of using a non-invasive fetal biomagnetometer to record and characterize aspects of fetal autonomic control of heart rate and variability and other neurobehaviors, we identified a group of women who were taking commercial DHA supplements during their pregnancy. In this small sample, we found lower fetal heart rate and higher fetal heart rate variability. This suggests that maternal DHA intake during pregnancy may have an effect on fetal cardiac autonomic control that results in lower mean heart rate and higher heart rate variability. To date, no one has investigated the effects of maternal DHA supplementation during pregnancy on fetal cardiac measures of rate and variability. The specific aims of this project are to evaluate the effect of maternal DHA supplementation during the 2nd and 3rd trimesters of pregnancy on maternal and fetal cardiac measures of rate and variability and fetal movements at 24 and 36 weeks gestational age. Additionally, we plan a postnatal assessment to determine the effect of supplementation on newborn neurobehavioral organization and infant heart rate and vagal control. This proposal is designed to test the hypothesis that maternal DHA intake (600 mg per day) given during the last two trimesters of pregnancy will increase maternal red blood cell phospholipid DHA and thus will have a positive influence on fetal cardiac autonomic nervous system regulation reflected in higher vagal control (reduced HR) and increased HRV. DHA will be provided via algal oil capsules while the placebo group will be provided capsules containing a combination of soybean and corn oils. This proposal is novel in that: 1) it is the first longitudinal exploration to determine the effects of maternal DHA supplementation during pregnancy on cardiac autonomic nervous system control of rate and variability from the 24 weeks gestational age to 2 months postnatal age 2) it is the first to explore the effects of supplementation during pregnancy on newborn neurobehavioral organization and 3) it uses a novel technology that is well suited to simultaneously measure the maternal and fetal magnetocardiogram (MCG) and fetal movements PUBLIC HEALTH RELEVANCE: Optimal fetal neurodevelopment is dependent on nutrients exclusively derived from dietary sources, including docosahexaenoic acid (DHA). DHA supplementation is of general public health interest because studies in adults have shown that dietary intake of DHA affects several cardiovascular disease risk markers including blood pressure and heart rate. The results of this study may have significant implications in regard to maternal- fetal nutrition, fetal programming of autonomic nervous system control, cardiac regulation and future cardiac health.
|
0.984 |
2016 — 2020 |
Gustafson, Kathleen M |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Prenatal Dha & Neurofunctional Development @ University of Kansas Medical Center
? DESCRIPTION (provided by applicant): Docosahexaenoic acid (DHA) is essential for neurodevelopment. If maternal DHA reserves are adequate during pregnancy, at parturition RBC-DHA of the mother would be ? the infant, i.e., DHA equilibrium. Previously, we randomized pregnant women to placebo oil or DHA (600 mg/day). We discovered that the majority of subjects did not achieve DHA equilibrium (5% placebo, 35% DHA), indicating DHA insufficiency, which has been reported to limit infant neurodevelopment. To test whether DHA insufficiency limited fetal neurodevelopment in our sample, we applied an innovative analysis method to estimate fetal brain maturation. Results confirmed that maternal DHA insufficiency significantly constrained fetal autonomic brain age scores (fABAS). Our hypothesis is that many pregnant women fail to get adequate DHA in their diet and that DHA insufficiency constrains fetal and infant neurodevelopment. The long-term goal is to provide the neuroscience to inform public health recommendations related to the use and dose of prenatal DHA supplementation, the influence of dietary fatty acids and the effect on offspring neurodevelopment. This is aligned with the strategic and scientific vision of NICHD and the mission of national and international health organizations that recognize that prenatal exposures set the stage for future health and disease. We propose a randomized Phase III clinical trial of 200 or 800 mg/day DHA during the last two trimesters of pregnancy to achieve these aims: Aim 1) Increase the incidence of DHA equilibrium with 800 mg/day maternal DHA supplementation. Hypothesis: The dosing strategy will result in significant group differences with a higher incidence of DHA equilibrium in the grou receiving 800 mg/day DHA supplementation. Aim 2) Establish whether failure to achieve DHA equilibrium constrains fetal neurodevelopment. Hypothesis: DHA insufficiency will constrain fetal neurodevelopment as evidenced by lower fetal cardiac and brain autonomic indices (HRV, fABAS) at 32 and 36 weeks GA. Aim 3) Determine if fetal neurodevelopmental scores predict infant neurodevelopment. Hypothesis: DHA insufficiency associated with lower fetal HRV and fABAS scores will have a programming effect evidenced by 1) lower band-limited EEG power at 1 month of age to infrequent auditory stimuli, 2) decreased habituation to familiar visual stimuli at 6 and 12 months, evidenced by a larger ERP negative central (NC) component and 3) reduced maintenance of sustained attention and longer overall ocular latency between 4-6 months. Relevance to Public Health: Currently, there are no FDA recommendations for DHA supplementation during pregnancy. If the aims of this proposal are achieved, it could lead to informed recommendations with respect to the appropriate use and effective dose of supplemental DHA and dietary recommendations during pregnancy, especially in populations where the nutritional status of the diet is suboptimal.
|
0.984 |